Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2025 Earnings Call Transcript
Operator: Good afternoon. Welcome to Sage Therapeutics First Quarter 2025 Financial Results Conference Call.
Sage Therapeutics Inc. (SAGE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Madison Avenue Partners Eli Samaha | 6,077,065 | $55,422,833 | +36% | 3.7% |
| 2. | Hudson Bay Capital Management Sander Gerber | 1,952,245 | $17,804,474 | +237% | 0.06% |
| 3. | D E Shaw D. E. Shaw | 1,917,284 | $17,485,630 | -9% | 0.01% |
| 4. | Balyasny Asset Management Dmitry Balyasny | 1,518,170 | $13,845,710 | +1235% | 0.02% |
| 5. | Alpine Associates Robert Emil Zoellner | 1,273,348 | $11,612,934 | 0.62% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.64 | 2,000 | $37,278.60 | 3,000 | 2023-08-09 | Filing | |
| $50.50 | 1,000 | $50,500.00 | 1,000 | 2023-05-09 | Filing | |
| $34.48 | 14,500 | $500,022.35 | 46,940 | 2022-11-10 | Filing | |
| $31.45 | 8,000 | $251,563.20 | 8,000 | 2022-05-05 | Filing | |
| $43.15 | 23,640 | $1,020,054.18 | 32,440 | 2021-08-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $44.90 | 3,838 | $172,328.89 | 121,981 | 2023-02-10 | Filing | |
| $44.47 | 7,805 | $347,083.67 | 125,819 | 2023-02-10 | Filing | |
| $160.58 | 8,000 | $1,284,640.00 | 2,535 | 2019-08-15 | Filing | |
| $171.39 | 475 | $81,410.54 | 12,115 | 2019-05-29 | Filing | |
| $170.40 | 400 | $68,158.00 | 12,590 | 2019-05-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,545,458 | $41,454,578 | 0% | |
| 2. | 3,265,802 | $29,784,115 | 0% | |
| 3. | 1,356,577 | $12,374,228 | 0% | |
| 4. | 1,166,002 | $10,633,938 | 0% | |
| 5. | 1,082,120 | $9,868,934 | 0.02% |
News See All
12 Best Psychedelic Stocks to Buy in 2025
In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality." One class of hallucinogenic substances that can produce unusual states of...
10 Best Small-Cap Growth Stocks to Buy Now
On November 4, 2024, Nick Sheridan, Portfolio Manager at Janus Henderson released a report on small-cap stocks exploring how these stocks offer unique growth and diversification opportunities.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to Sage Therapeutics Fourth Quarter and Full Year 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to Sage Therapeutics’ Third Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers
The U.S. Federal Reserve conducting a 50 basis point interest rate cut was the catalyst that stocks needed to bounce back from a period of stagnation.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. Welcome to Sage Therapeutics Second Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
Sage Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.8 EPS, expectations were $-1.63. Sage Therapeutics, Inc.
5 Best All-Time Stocks To Invest In
In this piece, we will take a look at the five best all time low stocks to invest in.
12 Best Depressed Stocks To Buy in 2024
JPMorgan Chief Jamie Dimon, in his latest letter to shareholders, has warned that the real odds of soft landing a quite low when compared to market expectations.